Miranova (Ethinylestradiol, Levonorgestrel)

Ethinylestradiol, the active ingredient in Miranova, is a combined oral contraceptive presented as a tablet for oral use. It works together with levonorgestrel, a progestogenic component that enhances contraceptive efficacy and contributes to cycle control, preventing pregnancy in women of reproductive age.

GNH USA supplies Miranova as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company follows stringent quality standards and provides reliable global distribution for this hormonal contraceptive.

Miranova, a combined oral contraceptive, is indicated for hormonal contraception and related menstrual management.

Contraception: Prevents unintended pregnancy in women of reproductive age. Menstrual cycle regulation: Provides more predictable bleeding patterns and reduces dysmenorrhea. Acne improvement: May lessen acne associated with androgen excess.

Miranova may cause a range of adverse reactions, which are generally classified by frequency and severity.

Common Side Effects: - Nausea - Headache - Breast tenderness - Weight gain - Mood changes - Spotting between periods

Serious or Rare Side Effects: - Venous thromboembolism - Pulmonary embolism - Stroke - Myocardial infarction - Severe hypertension - Liver tumor

Before prescribing Miranova, clinicians should evaluate individual risk factors and contraindications.

Contraindicated in women with a history of thromboembolic disorders: avoid use. Do not use in smokers over 35 years: increased cardiovascular risk. Assess blood pressure before initiating therapy: monitor regularly. Consider liver disease: adjust or avoid as needed. Review personal or family history of hormone‑dependent cancers: use with caution. Store at ambient temperature (below 25 °C): keep in original packaging, protect from moisture.

Miranova can interact with several medications that affect hormone metabolism or increase cardiovascular risk.

Major Interactions (Avoid): - Enzyme‑inducing anticonvulsants (e.g., carbamazepine, phenytoin): may reduce effectiveness. - Rifampin or other strong CYP3A4 inducers: may lead to contraceptive failure. - Antiretroviral protease inhibitors (e.g., ritonavir): may increase hormone levels, raising side‑effect risk.

Moderate Interactions (Monitor Closely): - Antibiotics such as rifampicin: may lower plasma concentrations; advise backup contraception. - St. John’s wort: may decrease efficacy, consider alternative. - Selective serotonin reuptake inhibitors (SSRIs): may increase risk of mood changes.